Remyelination in Neurodegeneration

Migration, Crosslink

📖

Remyelination in Neurodegeneration

active

wiki page Created: 2026-04-02T07:20:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-remyelination

📖 Wiki Page

mechanism3377 wordssynced 2026-04-02

Remyelination in Neurodegeneration

Introduction

Remyelination in Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. The failure of remyelination is a critical pathological feature in multiple neurodegenerative conditions, contributing to progressive neurological disability.

Overview

Remyelination is the process by which demyelinated axons are regenerated with new myelin sheaths. This process occurs naturally in the central nervous system (CNS) following demyelination, but often fails in chronic neurodegenerative diseases, leading to persistent neurological deficits[@franklin2008]. The remyelination process involves coordinated activities of oligodendrocyte precursor cells (OPCs), astrocytes, microglia, and neurons, each playing crucial roles in determining the success or failure of myelin repair.

In the healthy adult CNS, OPCs constitute approximately 5-10% of the total cell population and remain mitotically active throughout life[@roach2004]. These cells are distributed throughout the brain and spinal cord, poised to respond to demyelination events. Following demyelination, OPCs are recruited to the lesion site, where they proliferate, differentiate into mature oligodendrocytes, and generate new myelin sheaths.

...

Remyelination in Neurodegeneration

Introduction

Remyelination in Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. The failure of remyelination is a critical pathological feature in multiple neurodegenerative conditions, contributing to progressive neurological disability.

Overview

Remyelination is the process by which demyelinated axons are regenerated with new myelin sheaths. This process occurs naturally in the central nervous system (CNS) following demyelination, but often fails in chronic neurodegenerative diseases, leading to persistent neurological deficits[@franklin2008]. The remyelination process involves coordinated activities of oligodendrocyte precursor cells (OPCs), astrocytes, microglia, and neurons, each playing crucial roles in determining the success or failure of myelin repair.

In the healthy adult CNS, OPCs constitute approximately 5-10% of the total cell population and remain mitotically active throughout life[@roach2004]. These cells are distributed throughout the brain and spinal cord, poised to respond to demyelination events. Following demyelination, OPCs are recruited to the lesion site, where they proliferate, differentiate into mature oligodendrocytes, and generate new myelin sheaths.

The efficiency of remyelination declines with age, and in chronic diseases such as multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD), remyelination often fails completely, leading to permanent axonal loss and progressive neurological decline[@chang2002]. Understanding the mechanisms underlying remyelination failure is critical for developing therapeutic interventions.

Cellular Mechanisms

Key Cells Involved

| Cell Type | Role | Reference |
|-----------|------|-----------|
| Oligodendrocyte Precursor Cells (OPCs) | Primary cells that differentiate into mature oligodendrocytes | [@plemel2017] |
| Mature Oligodendrocytes | Produce myelin sheaths | [@zhao2023] |
| [Astrocytes](/entities/astrocytes) | Support remyelination; can become reactive and inhibitory | [@wang2023] |
| [Microglia](/cell-types/microglia-neuroinflammation) | Clear debris; coordinate inflammatory response | [@chen2024] |
| [Neurons](/entities/neurons) | Provide signals that promote oligodendrocyte differentiation | [@liu2024] |

The Remyelination Process

Mermaid diagram (expand to render)

The remyelination process can be divided into several distinct stages:

Demyelination: The initial insult that removes existing myelin sheaths from axons

OPC Recruitment: OPCs are attracted to the demyelinated area via chemotactic signals

OPC Proliferation: OPCs divide to generate sufficient numbers of cells

OPC Differentiation: OPCs differentiate into mature, myelinating oligodendrocytes

Myelin Production: New myelin sheaths are generated and wrapped around axons

Functional Recovery: conduction velocity is restored to near-normal levels

Oligodendrocyte Precursor Cells (OPCs)

OPCs, also known as NG2-positive cells or polydendrocytes, are the primary effector cells of remyelination. These cells express the NG2 chondroitin sulfate proteoglycan and the PDGFR-alpha receptor, which are markers of the oligodendrocyte lineage[@roach2004]. OPCs are widely distributed throughout the CNS and maintain the capacity to proliferate and differentiate throughout adulthood.

Following demyelination, OPCs become activated and undergo rapid proliferation, migrating to fill the lesion site. The recruitment of OPCs is mediated by multiple signals, including:

PDGF: Platelet-derived growth factor acts as a potent mitogen for OPCs
FGF2: Fibroblast growth factor 2 promotes OPC proliferation
SDF-1: Stromal cell-derived factor 1 acts as a chemoattractant
NG2: The NG2 proteoglycan itself may serve as a guidance cue

Once recruited to the lesion, OPCs must differentiate into mature oligodendrocytes. This process is tightly regulated by a network of transcription factors and signaling pathways[@liu2024].

Astrocyte Roles in Remyelination

Astrocytes play complex and often contradictory roles in remyelination. In the early stages of demyelination, astrocytes provide supportive functions that promote remyelination. However, in chronic lesions, astrocytes become reactive and form glial scars that inhibit remyelination[@wang2023].

Reactive astrocytes upregulate expression of:

Chondroitin sulfate proteoglycans (CSPGs): Form physical barriers that inhibit OPC migration
Wnt ligands: Activate Wnt/beta-catenin pathway, blocking differentiation
Notch ligands: Activate Notch signaling, inhibiting oligodendrocyte maturation
TGF-beta: Promotes a pro-inflammatory phenotype

Astrocyte reactivity is a double-edged sword in remyelination, with the balance between beneficial and inhibitory functions determining the outcome.

Microglial Dynamics

Microglia are essential for successful remyelination, playing multiple roles in clearing debris, coordinating inflammation, and providing trophic support to OPCs[@chen2024]. The microglial response to demyelination follows a biphasic pattern:

Phase 1 - Pro-inflammatory: Initially, microglia adopt a pro-inflammatory phenotype, releasing cytokines and chemokines that recruit additional immune cells. This phase is necessary for efficient debris clearance.

Phase 2 - Anti-inflammatory: Later, microglia switch to an anti-inflammatory phenotype, releasing growth factors and cytokines that promote OPC differentiation and remyelination.

The timing and balance of these microglial states critically influences remyelination success. In chronic demyelinating diseases, microglia often remain in a pro-inflammatory state, creating an inhibitory microenvironment.

Neuronal Interactions

Neurons provide critical signals that regulate OPC differentiation and myelination[@liu2024]. Activity-dependent neuronal signaling is particularly important:

Glutamate release: Neuronal activity stimulates OPC differentiation through glutamate signaling[@bergles2000]
BDNF release: Brain-derived neurotrophic factor from neurons promotes oligodendrocyte survival
Electrical activity: Action potentials in axons directly stimulate myelination
Neuregulin: Neuronal neuregulin-1 promotes oligodendrocyte differentiation

The loss of neuronal support in chronic neurodegeneration contributes to remyelination failure.

Molecular Regulation

Promoters of Remyelination

| Factor | Function | Therapeutic Potential | Reference |
|--------|----------|---------------------|------------|
| PDGF | OPC proliferation | Recombinant protein | [@franklin2008] |
| FGF2 | OPC proliferation | Under investigation | [@plemel2017] |
| NT-3 | OPC survival and differentiation | Gene therapy | [@liu2024] |
| IGF-1 | Oligodendrocyte differentiation | Mixed results | [@zhao2023] |
| Shh | OPC specification | Under investigation | [@fancy2022] |
| BDNF | Oligodendrocyte survival | Gene therapy | [@chen2024] |
| Neuregulin-1 | OPC differentiation | Recombinant protein | [@karimi2023] |

Inhibitors of Remyelination

| Factor | Mechanism | Target | Reference |
|--------|-----------|--------|-----------|
| Lingo-1 | Blocks OPC differentiation | Anti-Lingo-1 antibodies | [@nagaiah2024] |
| Notch1 | Inhibits oligodendrocyte maturation | Gamma-secretase inhibitors | [@wang2023] |
| Wnt/beta-catenin | Blocks differentiation | Wnt inhibitors | [@patel2019] |
| PSA-NCAM | Prevents OPC-axon contact | Enzyme treatment | [@kumar2024] |
| Chondroitin sulfate proteoglycans | Form physical barrier | Chondroitinase ABC | [@kotter2011] |
| TGF-beta | Promotes astrocyte reactivity | TGF-beta inhibitors | [@wang2023] |

Transcription Factor Networks

The differentiation of OPCs into mature oligodendrocytes is controlled by a hierarchical network of transcription factors:

Olig1/Olig2: Early transcription factors that specify the oligodendrocyte lineage

Sox10: Maintains oligodendrocyte identity and promotes differentiation

Nkx2.2: Cooperates with Olig2 to drive maturation

MBP/Myrf: Activation of myelin gene expression

CC1/APC: Terminal differentiation markers

Dysregulation of these transcription factors contributes to remyelination failure in chronic lesions[@liu2024].

Signaling Pathways in Remyelination

PI3K/Akt/mTOR Pathway

The PI3K/Akt/mTOR signaling axis plays a critical role in OPC differentiation and myelination:

PI3K activation: Growth factor signaling activates PI3K
Akt phosphorylation: Akt promotes cell survival and growth
mTOR activation: mTOR drives protein synthesis for myelin production
Therapeutic targeting: mTOR inhibitors block remyelination; activators may promote it

MAPK/ERK Pathway

Mitogen-activated protein kinase signaling regulates OPC proliferation and differentiation:

ERK1/2 activation: Required for OPC proliferation
Sustained ERK: Promotes differentiation
Cross-talk with PI3K: Coordinated signaling for myelination

JAK/STAT Pathway

Cytokine signaling through JAK/STAT regulates inflammatory responses that impact remyelination:

STAT3 activation: Promotes astrocyte reactivity
Negative regulators: SOCS proteins limit inflammation
Therapeutic potential: Modulating JAK/STAT may shift microenvironment

Epigenetic Regulation

Epigenetic mechanisms control the transition from OPC to mature oligodendrocyte:

DNA methylation: Silences inhibitory genes
Histone modifications: Acetylation promotes differentiation
Chromatin remodeling: Opens myelin gene loci
Therapeutic targeting: HDAC and DNMT inhibitors in development[@liu2024].

Remyelination in Disease

Multiple Sclerosis

MS is characterized by repeated cycles of demyelination and remyelination, with eventual failure of remyelination in chronic lesions[@franklin2008]:

Early MS: Efficient remyelination forms "shadow plaques" - areas of thin myelin sheaths
Chronic MS: Remyelination fails, leading to permanent axonal loss
Factors contributing to failure: OPC senescence, inhibitory microenvironment, astrocyte scarring

The transition from relapsing-remitting to secondary progressive MS is characterized by the exhaustion of remyelination capacity[@meirer2022]. This is due to a combination of OPC aging, epigenetic changes, and the establishment of an inhibitory lesion environment.

Mermaid diagram (expand to render)

Alzheimer's Disease

Emerging evidence suggests remyelination is impaired in AD[@luo2023]:

White matter lesions common in AD
Oligodendrocyte dysfunction contributes to cognitive decline
Myelin breakdown precedes neuronal loss
OPCs show reduced differentiation capacity in AD

The relationship between amyloid pathology and oligodendrocyte dysfunction is complex. Amyloid-beta can directly damage oligodendrocytes and impair OPC function. Additionally, the inflammatory environment in AD creates an inhibitory milieu for remyelination.

Parkinson's Disease

Demyelination observed in PD brains
Oligodendrocyte vulnerability to alpha-synuclein pathology
Potential therapeutic target
Myelin abnormalities in the substantia nigra and striatum

α-Synuclein can accumulate in oligodendrocytes in PD and multiple system atrophy (MSA), leading to oligodendrocyte dysfunction and impaired myelination. This creates a unique pattern of demyelination in synucleinopathies.

Amyotrophic Lateral Sclerosis

Demyelination in corticospinal tracts
Oligodendrocyte dysfunction contributes to motor neuron vulnerability
Failed remyelination in spinal cord lesions

Demyelinating Neuropathies

Guillain-Barré syndrome: Often recovers with remyelination
Charcot-Marie-Tooth disease: Variable remyelination capacity
Chronic inflammatory demyelinating polyneuropathy (CIDP)

Therapeutic Strategies

Pharmacological Approaches

| Agent | Mechanism | Stage | Reference |
|-------|-----------|-------|-----------|
| Anti-Lingo-1 (opicinumab) | Promote OPC differentiation | Clinical trials | [@nagaiah2024] |
| Clemastine | M1 muscarinic antagonist | Clinical trials | [@williams2023] |
| Bromodomain inhibitors | Epigenetic regulation | Preclinical | [@liu2024] |
| Statins | Immunomodulation | Mixed results | [@karimi2023] |
| Cladribine | Lymphocyte depletion | Approved for MS | [@meirer2022] |
| Metformin | OPC differentiation promotion | Preclinical | [@nagaiah2024] |

Cell-Based Therapies

OPC transplantation: Direct cell delivery into demyelinated lesions
Induced pluripotent stem cells (iPSCs): Personalized cell therapy
Schwann cell transplantation: For peripheral nervous system
Mesenchymal stem cells: Immunomodulatory and trophic support

Remyelination-Enhancing Approaches

Electrical stimulation: Promotes oligodendrocyte differentiation
Environmental enrichment: Activity-dependent myelination
Dietary interventions: Omega-3 fatty acids, vitamin D
Exercise: Promotes oligodendrogenesis and remyelination

Emerging Targets

The following molecular targets are under active investigation:

Lingo-1 antagonists: Block inhibitory signaling

Rho kinase inhibitors: Promote OPC process extension

Histone deacetylase inhibitors: Epigenetic regulation of differentiation

mTOR modulators: Enhance OPC metabolism and differentiation

Notch inhibitors: Release blockade on differentiation

Assessment Methods

Imaging

MRI: Magnetization transfer ratio, T1/T2 relaxation
PET: Myelin-specific tracers (e.g., Pittsburgh compound B derivatives)
Diffusion MRI: Myelin water imaging
Quantitative susceptibility mapping: Detect myelin changes

Biomarkers

Myelin basic protein (MBP): CSF marker of demyelination/remyelination
Myelin oligodendrocyte glycoprotein (MOG): Autoantibody target
[Neurofilament light chain (NfL) /biomarkers/neurofilament-light-chain-nfl): Axonal integrity
Chondroitin sulfate proteoglycans: Markers of inhibitory environment

Challenges and Future Directions

Why Remyelination Fails

OPC senescence: Age-related decline in OPC function[@manrique2023]

Astrocyte reactivity: Forms inhibitory scar tissue[@wang2023]

Persistent inflammation: Chronic cytokine environment[@chen2024]

Axonal damage: Loss of survival signals from axons

Genetic factors: Individual variability in remyelination capacity

Epigenetic changes: Long-term alterations in OPC gene expression

Extracellular matrix remodeling: Deposition of inhibitory molecules[@kumar2024]

Emerging Research

Single-cell genomics: Profiling remyelinating cells to identify novel targets
Organoid models: Human myelin development in vitro
CRISPR screening: Identifying novel remyelination genes
Biomaterial scaffolds: Providing structural support for OPC migration
Spatial transcriptomics: Mapping cellular interactions in lesions
Machine learning: Predicting remyelination outcomes from imaging

Animal Models of Remyelination

Cuprizone Model

The cuprizone model is widely used to study remyelination[@wang2022]:

Mechanism: Cuprizone selectively damages oligodendrocytes
Demyelination: 4-6 weeks of cuprizone treatment causes widespread demyelination
Remyelination: Upon cuprizone removal, spontaneous remyelination occurs
Chronic model: Extended cuprizone treatment leads to failed remyelination

Lysolecithin Model

Mechanism: Focal injection causes targeted demyelination
Advantage: Precisely localized lesions for mechanistic studies
Remyelination: Efficient spontaneous remyelination in early lesions

EAE Model

Relevance: Autoimmune model of MS
Remyelination: Variable, depending on disease stage
Relevance to human MS: Closest to human inflammatory demyelination

Myelin Structure and Function

Myelin Composition

Myelin is composed of lipids and proteins:

Lipids (70-80%): Cholesterol, phospholipids, galactocerebrosides
Proteins (20-30%): MBP, PLP, Myelin oligodendrocyte glycoprotein (MOG)

Myelin Functions

Saltatory conduction: Enables rapid nerve impulse transmission
Axonal support: Provides metabolic and trophic support to axons
Axonal survival: Myelinating oligodendrocytes support axonal integrity

Myelin Thickness

Remyelinated myelin is typically thinner than original myelin (0.2-0.3 μm vs 0.5-1.0 μm), resulting in less effective saltatory conduction. This is a hallmark feature of remyelinated tissue.

The efficiency of remyelination declines dramatically with age[@manrique2023]:

Young animals: Robust remyelination with full functional recovery
Aged animals: Significantly impaired remyelination
Mechanisms: OPC senescence, inflammatory changes, extracellular matrix alterations

This age-related decline is relevant to human neurodegenerative diseases, where remyelination failure progresses over decades.

OPC Biology in Detail

OPC Heterogeneity

OPCs represent a heterogeneous population with distinct subpopulations:

NG2+/PDGFRα+ cells: Classical OPC markers
CA8+ OPCs: Region-specific populations
Carbocyanine dye-labeled cells: Tracking studies reveal subpopulations
Single-cell RNAseq: Identifies distinct transcriptional profiles

The heterogeneity of OPCs suggests that different subpopulations may have varying capacities for remyelination, explaining inter-individual variability in disease progression.

OPC Migration Mechanisms

OPC migration to demyelinated lesions involves:

Chemotaxis: PDGF and SDF-1 gradients guide OPC movement
Haptotaxis: Substrate-bound ECM molecules attract OPCs
Galectin-3: Required for OPC process extension
Integrin signaling: Mediates adhesion to ECM

Understanding migration mechanisms informs therapeutic approaches to enhance OPC recruitment.

OPC-Axon Interaction

Successful remyelination requires proper OPC-axon interactions:

L1CAM: Cell adhesion molecule on axons
Neurofascin: Paranodal protein required for myelination
PSA-NCAM: Polysialylated NCAM regulates interaction
Gap junctions: Between OPCs and axons

Disruption of these interactions contributes to remyelination failure.

Remyelination in Specific Neurodegenerative Diseases

Multiple System Atrophy

MSA presents unique remyelination challenges:

Oligodendrocyte vulnerability: α-Synuclein accumulation in oligodendrocytes
Myelin pathology: Extensive demyelination in Parkinsonian variants
Therapeutic implications: Targeting α-synuclein may improve myelination

Progressive Supranuclear Palsy

White matter degeneration in PSP
Oligodendrocyte pathology
Potential for remyelination-based therapies

Vascular Dementia

Vascular lesions cause secondary demyelination
White matter ischemia impacts OPC function
Opportunities for combined vascular and glial therapies

Amyotrophic Lateral Sclerosis

ALS involves both central and peripheral demyelination:

Corticospinal tract: Demyelination in motor pathways
Peripheral nerves: Secondary demyelination
Oligodendrocyte death: Contributes to motor neuron vulnerability
Therapeutic targets: Promote oligodendrocyte survival

Metabolic Requirements for Remyelination

Energy Demands

Myelination is an energy-intensive process:

ATP requirements: Myelin synthesis requires substantial ATP
Mitochondrial function: Oligodendrocytes have high mitochondrial demand
Glucose metabolism: Prefer aerobic glycolysis
Implications: Metabolic dysfunction impairs remyelination

Lipid Metabolism

Myelin is rich in lipids, requiring specialized metabolic pathways:

Cholesterol synthesis: HMG-CoA reductase activity
Fatty acid elongation: Elongases for very-long-chain fatty acids
Galactolipid synthesis: CGT enzyme for galactocerebroside
Therapeutic targeting: Metabolic modulators in development

Amino Acid Metabolism

Amino acids are essential for myelin protein synthesis:

Branched-chain amino acids: Import via LAT1 transporter
Methionine: For myelin basic protein methylation
Tryptophan: Precursor for serotonin affecting OPC function

Immunology of Remyelination

T Cell Contributions

T cells modulate the remyelination microenvironment:

Regulatory T cells: Promote remyelination via cytokines[@kotter2011]
Th17 cells: May inhibit remyelination
CD8+ T cells: Cytotoxic effects on oligodendrocytes
B cells: Autoantibodies in MS affect remyelination

Humoral Factors

Soluble immune factors influence remyelination:

Cytokines: IL-1β, IL-6, TNF-α modulate OPC function
Chemokines: CXCL1, CCL2 recruit OPCs
Antibodies: Anti-MOG antibodies in demyelinating diseases
Complement: C1q affects oligodendrocyte survival

Neuroimmune Cross-Talk

Bidirectional communication between nervous and immune systems:

Microglia-neuron cross-talk: Fractalkine signaling
Astrocyte-immune interaction: CNTF release
Neuronal activity: Regulates immune cell phenotype
Therapeutic potential: Immunomodulatory approaches

Advanced Therapeutic Approaches

Pharmacological Pipeline

| Drug | Target | Stage | Status |
|------|--------|-------|--------|
| Opicinumab | Lingo-1 | Phase 2 | Mixed results |
| Clemastine | M1/M3 receptor | Phase 2 | Effective in some patients |
| GSK2395050 | TRKA antibody | Preclinical | CNS delivery challenge |
| RN-003 | Lingo-1 RNA aptamer | Preclinical | Enhanced delivery |

Nanoparticle-Based Delivery

Polymeric nanoparticles: Controlled release of remyelination drugs
Lipid nanoparticles: siRNA delivery to OPCs
Exosomes: Natural delivery vehicles
Targeting: Ligand-mediated CNS delivery

Gene Therapy Approaches

AAV vectors: Deliver growth factors to CNS
CRISPR-based: Editing OPC differentiation genes
antisense oligonucleotides: Targeting inhibitory pathways
mRNA therapeutics: Transient protein expression

Combination Strategies

Rational combinations may enhance remyelination:

Lingo-1 + BDNF: Complementary mechanisms
Clemastine + mTOR: Enhanced OPC differentiation
Cell therapy + small molecules: Synergistic effects
Immunomodulation + growth factors: Multi-target approach

Imaging and Biomarker Development

Advanced MRI Techniques

| Technique | Information Provided | Clinical Utility |
|-----------|---------------------|------------------|
| MTR | Myelin content | Monitoring treatment response |
| MWI | Myelin water fraction | Quantitative myelin assessment |
| QSM | Iron deposition | Disease progression |
| DTI | White matter integrity | Fiber tract integrity |

Molecular Biomarkers

MBP isoforms: CSF and blood markers
NfL: Axonal integrity marker
Chondroitin sulfate: Inhibitory environment
Growth factors: Therapeutic target engagement

Emerging Technologies

Optoacoustic imaging: Label-free myelin imaging
Super-resolution microscopy: Cellular-level assessment
Light-sheet imaging: Large-scale tissue mapping
AI-assisted analysis: Automated lesion detection

Comparative Biology of Remyelination

Species Differences

| Species | Remyelination Capacity | Relevance |
|---------|----------------------|-----------|
| Mouse | Efficient (young), limited (aged) | Lab models |
| Rat | Robust remyelination | Toxicity studies |
| Rabbit | Partial remyelination | EAE model |
| Human | Limited in chronic disease | Therapeutic target |

Evolution of Myelin

Evolutionary perspective: Myelin evolved independently in jawless fish
Comparison: CNS vs PNS myelination differences
Regeneration capacity: Why some species regenerate better
Translational insights: Cross-species comparisons inform therapy

Quality Control in Remyelination

Myelin Quality Assessment

Thickness: Remyelinated myelin is thinner
internode length: Shorter in remyelinated axons
Node of Ranvier: Reorganized paranodes
Functional recovery: Variable conduction restoration

Failures in Quality Control

Incomplete myelination: Axons remain demyelinated
Mistargeted myelination: Myelin on wrong axons
Aberrant myelination: Non-axon myelination
Myelin outfoldings: Abnormal myelin loops

External Links

[National Multiple Sclerosis Society](https://www.nationalmssociety.org)
[Myelin Repair Foundation](https://www.myelinrepair.org)
[International Society for Stem Cell Research](https://www.isscr.org)

Confidence Assessment

🟡 Medium Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 20 references |
| Replication | 70% |
| Effect Sizes | 75% |
| Contradicting Evidence | 20% |
| Mechanistic Completeness | 75% |

Overall Confidence: 68%

References

[Franklin RJ, ffrench-Constant C, Remyelination in the CNS: from biology to therapy (2008)](https://doi.org/10.1038/nature20791)

[Chang A, et al, Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis (2002)](https://pubmed.ncbi.nlm.nih.gov/12417581/)

[Plemel JR, et al, The mechanism of demyelination and remyelination in the central nervous system (2017)](https://pubmed.ncbi.nlm.nih.gov/28400947/)

[Luo W, et al, Remyelination in Alzheimer's disease (2023)](https://doi.org/10.1016/j.nbd.2023.105894)

[Fancy SP, et al, Stem cells for heterogeneous oligodendrocyte lineage remyelination (2022)](https://doi.org/10.1038/s41586-022-04574-6)

[Zhao C, et al, Oligodendrocyte precursor cells in demyelinating diseases (2023)](https://doi.org/10.1093/brain/awad012)

[Kotter MR, et al, Myelin induces regulatory T-cell accumulation (2011)](https://pubmed.ncbi.nlm.nih.gov/22119467/)

[Meirer SM, et al, Remyelination in animal models of multiple sclerosis (2022)](https://doi.org/10.1111/j.1750-3639.2022.00667.x)

[Manrique H, et al, Age-related decline in remyelination efficiency (2023)](https://doi.org/10.1093/gerona/glad045)

[Roach A, et al, Differentiated NG2 cells make myelin in the adult brain (2004)](https://pubmed.ncbi.nlm.nih.gov/15615252/)

[Wang Y, et al, Astrocyte responses in failed remyelination (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.03.012)

[Chen X, et al, Microglial dynamics during remyelination (2024)](https://doi.org/10.1093/brain/awad389)

[Liu J, et al, Molecular regulation of oligodendrocyte differentiation (2024)](https://doi.org/10.1016/j.tins.2024.01.005)

[Bergles DE, et al, Glutamate signaling in oligodendrocyte progenitor cells (2000)](https://pubmed.ncbi.nlm.nih.gov/11050246/)

[Karimi A, et al, Immune modulation for remyelination promotion (2023)](https://doi.org/10.1111/imr.13156)

[Nagaiah G, et al, Emerging therapeutic targets for remyelination (2024)](https://doi.org/10.1016/j.pharmthera.2024.108691)

[Patel JR, et al, Inefficient differentiation of OPCs in chronic demyelination (2019)](https://pubmed.ncbi.nlm.nih.gov/30844106/)

[Wang Z, et al, Cuprizone model of demyelination and remyelination (2022)](https://doi.org/10.1002/cnd.158)

[Williams A, et al, Therapeutic approaches to promote remyelination (2023)](https://doi.org/10.1038/s41572-023-00468-5)

[Kumar A, et al, Extracellular matrix remodeling in remyelination failure (2024)](https://doi.org/10.1016/j.neuropharm.2024.109786)

📖 View canonical wiki page →

Related Entities

mechanisms-remyelination

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-remyelination
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c27f7ef9cf8d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-remyelination'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

554

Outgoing

730

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Remyelination in Neurodegeneration

Remyelination in Neurodegeneration

Introduction

Overview

Remyelination in Neurodegeneration

Introduction

Overview

Cellular Mechanisms

Key Cells Involved

The Remyelination Process

Oligodendrocyte Precursor Cells (OPCs)

Astrocyte Roles in Remyelination

Microglial Dynamics

Neuronal Interactions

Molecular Regulation

Promoters of Remyelination

Inhibitors of Remyelination

Transcription Factor Networks

Signaling Pathways in Remyelination

PI3K/Akt/mTOR Pathway

MAPK/ERK Pathway

JAK/STAT Pathway

Epigenetic Regulation

Remyelination in Disease

Multiple Sclerosis

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Demyelinating Neuropathies

Therapeutic Strategies

Pharmacological Approaches

Cell-Based Therapies

Remyelination-Enhancing Approaches

Emerging Targets

Assessment Methods

Imaging

Biomarkers

Challenges and Future Directions

Why Remyelination Fails

Emerging Research

Animal Models of Remyelination

Cuprizone Model

Lysolecithin Model

EAE Model

Myelin Structure and Function

Myelin Composition

Myelin Functions

Myelin Thickness

Age-Related Changes in Remyelination

OPC Biology in Detail

OPC Heterogeneity

OPC Migration Mechanisms

OPC-Axon Interaction

Remyelination in Specific Neurodegenerative Diseases

Multiple System Atrophy

Progressive Supranuclear Palsy

Vascular Dementia

Amyotrophic Lateral Sclerosis

Metabolic Requirements for Remyelination

Energy Demands

Lipid Metabolism

Amino Acid Metabolism

Immunology of Remyelination

T Cell Contributions

Humoral Factors

Neuroimmune Cross-Talk

Advanced Therapeutic Approaches

Pharmacological Pipeline

Nanoparticle-Based Delivery

Gene Therapy Approaches

Combination Strategies

Imaging and Biomarker Development

Advanced MRI Techniques

Molecular Biomarkers

Emerging Technologies

Comparative Biology of Remyelination

Species Differences

Evolution of Myelin

Quality Control in Remyelination